This multicenter, double-blind, randomized, parallel study compared the efficacy and safety of two dosages of naproxen sodium (NS) in 100 patients with bone pain due to rne~stati~ cancer. Patients were asked to rate their pain on a scale of O-99; those patients with pain scores of 40 or more (indicating moderate to severe pain) were enrolled. Patients receiving the high-dosage regimen (HDR; n = 51) received NS 550 mg every 8 h for 3 days. Those receiving the low-dosage regimen (LDR; n = 49) received on day 1 an initial dose of NS 550 mg followed by NS 275 mg capsules every 8 h through day 3. Patients evaluated pain intensity 8 times/day. During use of NS, pain intensity scores decreased by approximately one-third in each treatment group. Among patients who responded to NS, pain relief with the HDR was significantly greater than with the LDR. Differences between regimens in adverse events during treatment were non-significant; complaints were mainly gastrointestinal and mild.
Introduction
acetaminophen or oral pentazocine, naproxen sodium provided greater relief in patients with Non-steroidal anti-inflammatory drugs (NSAImoderate to severe postoperative pain [4, 8] . Ds) are among the most commonly prescribed Naproxen sodium, like other members of the drugs for the relief of mild to moderate pain.
NSAID class of drugs, produces analgesia priSome investigators have found that the NSAID marily by inhibiting the synthesis of prostaglannaproxen sodium is also effective in relieving dins. In cancer patients, the pain associated with moderate to severe musculoskeletal, postoperative, bony metastases appears to be mediated by prospost-partum, and dysmenorrheic pain [1,4,5,X0,11 1.
In double-blind studies, when compared to taglandins [7, 9, 12] , with both PGE, and PGE, producing hyperalgesia through nociceptor sensitization [3] . The analgesic efficacy of naproxen sodium, coupled with its good tolerability, warranted investigation of this prostaglandin in~bitor 
